Literature DB >> 8921499

Health effects of human T-lymphotropic virus type I (HTLV-I) in a Jamaican cohort.

E L Murphy1, R Wilks, O S Morgan, B Hanchard, B Cranston, J P Figueroa, W N Gibbs, J Murphy, W A Blattner.   

Abstract

BACKGROUND: Other than adult T-cell leukaemia (ATL) and HTLV-I associated myelopathy (HAM), the health effects of infection with human T-lymphotropic virus type I (HTLV-I) are not well defined.
METHOD: A cohort of 201 confirmed HTLV-I seropositive Jamaican food service workers and 225 seronegative controls of similar age and sex from the same population was examined. A health questionnaire, physical examination, and laboratory tests were performed at enrollment into the cohort in 1987-1988.
RESULTS: One of 201 HTLV-I seropositives, but no controls were diagnosed with HAM, for a prevalence of 0.5% (95% confidence interval) (CI) 0.01-2.7%); no cases of ATL were diagnosed. While there was no difference in current symptoms, the HTLV-I seropositive group was more likely to report a past medical history of hepatitis or jaundice (OR = 3.49, 95% CI: 0.93-13.08), malaria (OR = 2.13, 95% CI: 0.96-4.73), and dengue fever (OR = 1.37, 95% CI: 0.82-2.29); however, these differences were of borderline statistical significance. Low income HTLV-I seropositive women had lower body weight (P < 0.01) and body mass index (P < 0.009) than their seronegative counterparts; similar differences were seen in the smaller male group. A trend toward higher prevalence of severe anaemia (haemoglobin < 10 g/dl) (12.6% versus 7.7%, P < 0.105) and a significantly lower prevalence of eosinophilia (1.0% versus 6.3%, P < 0.004) was seen among HTLV-I seropositives compared to controls.
CONCLUSIONS: Although most HTLV-I seropositives are asymptomatic, HAM may be diagnosed in approximately 0.5% of carriers. Chronic HTLV-I infection may also exert subtle effects on body mass and haematological parameters.

Entities:  

Mesh:

Year:  1996        PMID: 8921499     DOI: 10.1093/ije/25.5.1090

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  7 in total

1.  Quantitative assessment of subclinical spasticity in human T-cell lymphotropic virus type I infection.

Authors:  J R Zunt; J O Alarcón; S Montano; W T Longstreth; R Price; K K Holmes
Journal:  Neurology       Date:  1999-07-22       Impact factor: 9.910

2.  Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection.

Authors:  Melissa T Bartman; Zhanna Kaidarova; Dale Hirschkorn; Ronald A Sacher; Joy Fridey; George Garratty; Joan Gibble; James W Smith; Bruce Newman; Anthony E Yeo; Edward L Murphy
Journal:  Blood       Date:  2008-08-28       Impact factor: 22.113

3.  Clinical manifestations associated with HTLV type I infection: a cross-sectional study.

Authors:  Marina F Caskey; Daniel J Morgan; Aurelia F Porto; Silvana P Giozza; Andre L Muniz; Glória O Orge; Maria J Travassos; Yolanda Barrón; Edgar M Carvalho; Marshall J Glesby
Journal:  AIDS Res Hum Retroviruses       Date:  2007-03       Impact factor: 2.205

4.  Editorial Commentary: Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) and HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

Authors:  Graham P Taylor
Journal:  Clin Infect Dis       Date:  2015-03-27       Impact factor: 9.079

5.  Clinical associations of Human T-Lymphotropic Virus type 1 infection in an indigenous Australian population.

Authors:  Lloyd Einsiedel; Tim Spelman; Emma Goeman; Olivier Cassar; Mick Arundell; Antoine Gessain
Journal:  PLoS Negl Trop Dis       Date:  2014-01-16

6.  Mortality associated with HIV-1, HIV-2, and HTLV-I single and dual infections in a middle-aged and older population in Guinea-Bissau.

Authors:  Birgitta Holmgren; Zacarias da Silva; Pernille Vastrup; Olav Larsen; Sören Andersson; Henrik Ravn; Peter Aaby
Journal:  Retrovirology       Date:  2007-11-27       Impact factor: 4.602

7.  Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors.

Authors:  K Arisawa; M Soda; M Akahoshi; T Matsuo; E Nakashima; M Tomonaga; H Saito
Journal:  Jpn J Cancer Res       Date:  1998-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.